Testing to Diagnose Hormone-Secreting Pituitary Tumors

Pituitary adenomas account for approximately 15% of intracranial tumors. Management of these benign tumors requires diagnosis of the specific intrasellar disease and comprehensive, multidisciplinary treatment of local mass effects and peripheral endocrinopathies. Since tumors can produce different hormones, their consequences and management vary widely. Continue reading

Criteria to Initiate Evaluation for Growth Hormone Deficiency (GHD)

Tools for the diagnosis of GHD include auxology, radiographic assessment of bone age, measurement of insulin-like growth factor 1 (IGF-I) and IGF binding protein 3 (IGFBP-3), provocative growth hormone (GH) testing, cranial magnetic resonance imaging (MRI), and, in certain cases, genetic testing. Growth velocity and the degree of short stature are primary considerations in the decision to pursue evaluation for GHD. Continue reading